A Phase II Study to Determine the Efficacy of Tarceva (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase II Study to Determine the Efficacy of Tarceva (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 03 Nov 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov.
    • 01 Jul 2014 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top